PRKDC and prostate carcinoma: In this work, Ni et al. showed that DNAPK PSMA-based targeted inhibition sensitized LNCaP prostate cancer cells to ionizing radiation, as shown in in vitro MTS assays where the aptamer-shRNA chimera increased cell death after IR cycles but not the controls.